Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Boeson Research

Neither a doctor nor a teaching hospital

Research payments

$1,338,861

314 payments

Through program year 2025, Boeson Research is reported as receiving $1,338,861 in research payments, across 314 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $599,831 222
2024 Research $193,387 23
2023 Research $103,741 17
2022 Research $58,781 7
2021 Research $4,276 16
2020 Research $221,824 21
2019 Research $157,022 8

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $423,170 72 payments
  2. Seqirus USA Inc $280,387 121 payments
  3. Sanofi Pasteur Inc. $186,715 72 payments
  4. Amgen Inc. $172,755 6 payments
  5. AstraZeneca Pharmaceuticals LP $109,078 5 payments
  6. GlaxoSmithKline, LLC. $47,890 24 payments
  7. Sanofi US Services Inc. $38,284 4 payments
  8. Abbott Laboratories $30,944 2 payments
  9. Incyte Corporation $30,045 7 payments
  10. Celgene Corporation $19,594 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2 Placebocontrolled Randomized Proof of Concept Study of A Respiratory Syncytial Virus RSV Vaccine in Pregnant Women $347,579 24 payments
  2. A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age $274,393 117 payments
  3. Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) $103,497 29 payments
  4. Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) $88,788 39 payments
  5. Ph3 Otezla in Peds mild/mod PsO PMR $85,271 2 payments
  6. A Phase 1 Openlabel Study to Evaluate the Pharmacokinetics Safety and Tolerability of Orally Administered Nirmatrelvirritonavir in Pregnant Women With Mildtomoderate Covid19 $59,607 8 payments
  7. a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure $47,875 1 payment
  8. Ph3 Otezla in Peds mild/mod PsO (PMR) $37,230 1 payment
  9. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity $31,556 1 payment
  10. FreeStyle Libre 2 Flash Glucose Monitoring System Control Phase Study for Pediatric Patients - BG $30,550 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record